Lista de obras -

A Distinct Immunophenotypic Profile Of Del(5q) MDS Allows For Fast Monitoring Of Response To Treatment With Lenalidomide Or Azacitidine ⬇️

artículo científico publicado en 2013

A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients

artículo científico publicado en 2018

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse

artículo científico publicado en 2022

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial ⬇️

scholarly article

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial

artículo científico publicado en 2018

Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)

artículo científico publicado en 2020

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

artículo científico publicado en 2021

Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

scientific article published on 01 December 2018

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis

artículo científico publicado en 2021

Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears

artículo científico publicado en 2021

Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML

artículo científico publicado en 2022

Discriminant Principal Component Analysis of ToF-SIMS Spectra for Deciphering Compositional Differences of MSC-Secreted Extracellular Matrices

artículo científico publicado en 2023

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

artículo científico publicado en 2021

H1N1-09 Infections In Patients with Hematologic or Oncologic Malignancies: A Single-Centre Experience ⬇️

artículo científico publicado en 2010

Hip Pain in Medulloblastoma as First Symptom of Extraneural Relapse ⬇️

artículo científico publicado el 23 de marzo de 2011

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

artículo científico publicado en 2020

Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia

artículo científico publicado en 2014

Is it already time for combination treatment in lower risk MDS?

scientific article published on 01 December 2012

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

artículo científico publicado en 2012

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial

artículo científico publicado en 2017

Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms

artículo científico publicado en 2021

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation

artículo científico publicado en 2012

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

artículo científico publicado en 2018

Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome

artículo científico publicado en 2015

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

artículo científico publicado en 2011

Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag ⬇️

artículo científico publicado en 2013

Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring

artículo científico publicado en 2014

Nanocytometer for smart analysis of peripheral blood and acute myeloid leukemia: a pilot study

artículo científico publicado en 2020

Optimizing management of myelodysplastic syndromes post-allogeneic transplantation

artículo científico publicado en 2011

POTENTIAL ROLE of 8-COLOR FLOW CYTOMETRY for CHARACTERIZATION of MDS with Del(5q) ABNORMALITIES ⬇️

artículo científico publicado en 2011

Parvovirus B19 Infection

scientific article published on 01 December 2018

Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow

artículo científico publicado en 2013

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

artículo científico publicado en 2021

Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease - ⬇️

artículo científico publicado en 2013

Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience ⬇️

artículo científico publicado en 2015

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

scientific article published on 03 December 2019

Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients ⬇️

scholarly article

Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells

scientific article published in 2022

Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro

artículo científico publicado en 2021

The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial

scientific article published on 29 August 2019

Treating myelodysplastic syndromes by nuclear transport inhibition

artículo científico publicado en 2020

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients ⬇️

artículo científico publicado en 2015

Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2018

When to transplant MDS, and what to do when transplant fails

artículo científico publicado en 2013

Lista de obras de

A Distinct Immunophenotypic Profile Of Del(5q) MDS Allows For Fast Monitoring Of Response To Treatment With Lenalidomide Or Azacitidine ⬇️

A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial ⬇️

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial

Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis

Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears

Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Discriminant Principal Component Analysis of ToF-SIMS Spectra for Deciphering Compositional Differences of MSC-Secreted Extracellular Matrices

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

H1N1-09 Infections In Patients with Hematologic or Oncologic Malignancies: A Single-Centre Experience ⬇️

Hip Pain in Medulloblastoma as First Symptom of Extraneural Relapse ⬇️

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia

Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia

Is it already time for combination treatment in lower risk MDS?

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial

Long-Term Mixed Chimerism After <i>Ex Vivo</i>/<i>In Vivo</i> T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag ⬇️

Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring

Nanocytometer for smart analysis of peripheral blood and acute myeloid leukemia: a pilot study

Optimizing management of myelodysplastic syndromes post-allogeneic transplantation

POTENTIAL ROLE of 8-COLOR FLOW CYTOMETRY for CHARACTERIZATION of MDS with Del(5q) ABNORMALITIES ⬇️

Parvovirus B19 Infection

Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease - ⬇️

Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience ⬇️

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients ⬇️

Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells

Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression <i>in Vitro</i>

The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial

Treating myelodysplastic syndromes by nuclear transport inhibition

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients ⬇️

Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

When to transplant MDS, and what to do when transplant fails